Reputation
-
Lilly set to disrupt medicines supply chain
- Wed Sep 23
LillyDirect may well be to community pharmacy what Uber was to taxis; taxis are still there, but if given a choice, most people choose Uber.
Read more -
In defence of the humble omnibus survey
- Mon Sep 21
In response to an op-ed on omnibus surveys, The Advisory Ward’s Will Collie argues they are of value – it all depends on the question.
Read more -
A thousand opinions, zero insights
- Fri Sep 18
OP-ED: Use of consumer surveys for media releases can be lazy public relations, not telling journalists anything other than the bleeding obvious.
Read more -
Doctors demand companies act on misinformation
- Fri Sep 11
EXCLUSIVE: Fed up with misinformed patients, Australian clinicians say pharma companies must correct the record or face prescriber backlash.
Read more -
Lilly ANZ policy head leaves for mental health gig
- Wed Aug 26
After an impressive stint in pharma that saw Lilly take a fresh approach to media and access, Katherine Burchfield has left to lead a mental health service.
Read more -
Is PBAC finally measuring up, or just hitting out?
- Mon Aug 24
Industry pushed for better metrics on PBS listings. The PBAC has finally obliged, but this is unlikely to be what anyone asked for.
Read more -
Sobi tops with rare disease patients
- Fri Aug 21
Beats Roche, Boehringer to win best reputation among rare disease patients, but it is Viatris’ meteoric rise that makes it one to watch.
Read more -
Indian PR giant buys control of SenateSHJ
- Fri Aug 21
Adfactors PR acquires a majority stake in SenateSHJ, a major provider of media and corporate affairs services to the ANZ pharma and MedTech sectors.
Read more